On the other hand, in phase 2 and 3 clinical trials, an increase of 4.2 and 2.9 months in overall survival was observed, respectively, with the administration of atezolizumab (anti-PD-L1) compared to chemotherapy with docetaxel in patients with NSCLC (49). The gene discussed is CD274; the disease is non-small cell lung carcinoma.